Using the Tandem'P-E, Axsyrnw and LIA-mat® assays, prostate specific antigen (PSA) was measured in pure PSA solutions of known concentrations of free and complexed PSA and in serum of patients with prostate cancer (n = 31), benign prostate hyperplasia (n = 32) and in healthy controls (n = 27). Measurements of pure PSA solutions showed that the AxSym® assay exemplified typical properties of the skewed-response assay reacting more to free PSA than to the complexed PSA forms whereas the other two assays showed an equimolar-response. When PSA was measured in the serum of the three groups, the AxSym® test and Tandem'v-E gave similar PSA values whereas' the LIA-mat test yielded significantly lower values. These results were not related to the amount of free PSA in the samples and proved that discordant PSA values between PSA assays were not mainly caused by the use of skewed-or equimolar assays. Despite these differences, receiver-operation characteristic analysis confirmed that the clinical validity of all three PSA tests did not differ.
Additional key phrases: prostate cancer; benign prostate hyperplasia; tumour marker; receiver operation curve Prostate specific antigen (PSA) exists in serum in multiple forms. About 80% of serum PSA found in healthy men is complexed to the protease inhibitors IXI-antichymotrypsin (ACT), lXI-antitrypsin and 1X2-macroglobulin.l,2 The rest of serum PSA occurs as free, non-complexed PSA (f-PSA).1,2 The PSA-ACT complex is the major form of these PSA complexes whereas the PSA bound with the other two inhibitors is only found in small concentrations.l-'
The occurrence of multiple forms of PSA is very important both from a clinical and analytical point of view. Recent reports have indicated that patients with prostate cancer (PCa) have a higher proportion of ACT-PSA than patients with benign prostatic hyperplasia (BPH)2-5 and there are differences between various PSA assays when measuring free or Correspondence: Dr Klaus Jung. protein-bound PSA forms. 2.6 • 7 Tillyer et al. 6 recently discussed in this Journal the problem of the disagreement between the Roche Cobas® Core and the Hybritech Tandem®-E PSA assays when measuring the f-PSA and the PSA-ACT complex. Similar problems were described when PSA values were compared between the Ciba Corning ACS:180'K PSA assay and the Hybritech Tandems' PSA assay." The discordant values seen in these comparisons were partly explained by the so-called skewed response of the Roche Cobasw Core PSA assay and Ciba Corning ACS: 180® PSA assay in contrast to the equimolar response of the Tandemw-E PSA test.s? An 'equimolar assay' is defined as an assay which measures f-PSA and ACT-PSA equally whereas the 'skewed-response assay' preferentially measures f-PSA compared to ACT-PSA.7 Consequently, a skewed-response assay would underestimate the PSA in PCa patients with lower free PSA and would be disadvantageous for the detection of prostatic cancer."
How do these effects influence the clinical significance of serum PSA measurements? To answer this question, we have performed PSA determinations on solutions of varying ratios of f-PSA/ACT-PSA and in the serum of healthy men and patients with BPH and PCa using three PSA assays (Tandem®-E; AxSym®, LIA-mat®).
METHODS

Patients and samples
A total of 90 men was studied, including a control group of 27 healthy men [mean age (SD): 57± II years], 31 patients (mean age: 66±8 years) with PCa of the stages B, C, D, and 32 patients (mean age: 69 ± 9 years) with BPH. All samples were taken before initiation of therapy. The diagnosis of BPH was based either on histological analysis of tissue obtained by transurethral resection of the prostate (n = 27) or was clinically confirmed. The diagnosis of PCa was obtained cytopathologically by transrectal fine needle biopsy or histopathologically by microscopic examination of prostatic specimens after biopsy or prostatectomy.
Blood was collected before digital rectal examination and instrumentation. The serum was obtained by centrifugation at 1500rcm for 10min after allowing the blood to clot for 1 h at room temperature. The serum samples were analysed either the same day or stored at -70 DC before analysis.
Pure PSA solutions of known composition were obtained from Hybritech. PSA materials were prepared by immunoaffinity column chromatography and were characterized by electrophoresis, column chromatography, gel filtration and quantitative amino acid analysis. Sample I contained 100% f-PSA, sample 2 100% ACT-PSA and sample 3 was a mixture of sample 1 and sample 2 in equal parts. Further gradations of PSA fractions were made by mixing the samples. The samples (20 ul: per vial) were stored at -20 DC and were diluted with I mL diluent (human serum albumin solution) from the LIA-mat® assay 2 h before analysis. Previous experiments of diluting serum samples having PSA concentrations> 5000 Ilg/L with the diluents of the three assays or female serum showed no effect of the respective diluent on the PSA concentration measured by the three assays. Thus, the diluent from LIA-mat® was Ann Clin Biochem 1996: 33 also valued in the AxSym® and Tandem'S assays.
PSA assays
We used the Tandem'P-E PSA assay (Hybritech, San Diego, CA, USA), the AxSym® PSA assay (Abbott Labs, Abbott Park, IL, USA) and the LIA-mat® PSA assay (Byk-Sangtec GmbH, Dietzenbach, Germany). The Tandem®-E test and the LIA-mat® test use two monoclonal anti-PSA antibodies whereas the AxSym® test is based on the monoclonal-polyclonal architecture.
The Tandem'v-E assay is a two-site immunoenzymetric test based on the sandwich principle. Plastic beads coated with a monoclonal antibody against PSA serve as a solid phase. Samples, standards and controls containing PSA react with this antibody and with a second labelled with alkaline phosphatase. The bead containing the antibody-antigen complex is washed to remove unbound enzyme-labelled antibody and is then incubated with the enzyme substrate 4-nitrophenyl phosphate. The released 4-nitrophenol is measured in the immunoassay analyser Photon II (Hybritech).
The AxSym®-PSA assay is a micro particle enzyme immunoassay. The sample is incubated with micro particles coated with monoclonal antibodies which bind a specific epitope of PSA. An aliquot of the reaction mixture is pipetted into a special reaction cell where the microparticles bind irreversibly to a glass fibre matrix. Unbound materials are removed by washing and anti-PSA antibody labelled with alkaline phosphatase is added which binds to the antibody-antigen complex. The unbound components are removed, the substrate 4-methylumbelliferyl phosphate is added and fluorescent 4methylumbelliferone is released which is measured on the immunoassay analyser AxSym.
The LIA-mat assay is a two-site immunoluminometric sandwich assay. Two different highly specific monoclonal antibodies are used for coating the tube and for the tracer. The tracer antibody and the antibody of the tube react simultaneously with the PSA present in patient samples and standards. Unbound PSA is removed by a washing step. The tracer consists of an antibody bound to an isoluminol derivative. The tracer-PSA-complex bound to the tube wall during incubation is measured by the luminogenic reaction started by the injection of alkaline peroxide solution and detected at 425nm.
to ACT-PSA but the same total PSA concentration. Fig. 1 shows the results of measured PSA in these solutions. It demonstrates that:
Influence of the free prostate-specific antigen (PSA) on the measured PSA value. Samples with a declared valuefor total PSA of about 4/lg/L but varying proportions of free and complexed PSA were measured using Tandem®-E test (0), LIA-mat® test (JII.) . and AxSym® test (0). For further details: see text.
PSA values measured by the Tandem®-E assay and the LIA-mat® are independent of the f-PSA composition and correspond to the typical behaviour of the equimolar-response assay defined by Strobel et al. ' 2 The AxSym® test gave higher PSA values in specimens with the higher proportion of f-PSA and was a typical skewed-response assay 3 The LIA-mat® assay gave higher PSA values than the Tandem'P-E test (about 5·5 versus 4'3/lg/L) although both tests behave as equimolar-response assays.
PSA values measured by the Tandem'P-E and AxSym® test did not differ when the respective group was compared (Table 1) . Studies comparing these two assays using the nonparametric linear regression procedures showed that intercepts and the slopes separately calculated for all groups were not different from zero and 1, respectively ( Table 2 ). All these data indicated that the typical skewed-response effect of the AxSym® test in the pure solution was not found when serum was measured. This experiment showed that the two assays would give results not differing by more than 10%, provided that f-PSA in serum was in the range between 10 to 50% of the total PSA (Fig. 1 ). Similar results were described by Bankson The specific PSA solutions supplied by Hybritech contained different ratios of f-PSA All three tests were calibrated with their own calibrators. The measurements were performed for all methods on the same day. All values were within the measuring range of the respective method so that dilution of samples was not necessary. Quality control was performed using pooled sera and control materials supplied by the producers of the test kits. The results for quality control materials were within the ranges quoted by the manufacturers. The between-run precision was measured by using pooled human serum (4,5/lg/l; Tandemw), The coefficient of variation was below 5% for all three methods.
f-PSA was measured using Immulite'P Free PSA assay (Diagnostic Products Corp, Los Angeles, USA). This is a solid-phase, two-site sequential chemiluminescent immunometric test and is automatically handled on the Immulite'P Automated Analyzer. During a first incubation, f-PSA of the sample binds to a polystyrene bead coated with murine monoclonal anti-PSA antibody specific for f-PSA. Unbound PSA forms are then removed by a centrifugal wash. In the second incubation cycle, an alkaline phosphatase-labelled polyclonal goat anti-PSA antibody binds to the f-PSA/anti-f-PSA antibody complex. Unbound enzyme conjugate is removed by a centrifugal wash and the bound enzyme splits the added chemiluminescent substrate lumigen, a phoshate ester of adamantyl dioxetane. This results in an unstable intermediate with an emission of photons measured by the luminometer of the analyser. F-PSA was related to the total PSA concentration measured by Tandem's assay and expressed as the percentage of f-PSA. Since commercial f-PSA assays were not available at the start of the study, f-PSA was not measured on all samples.
Statistical calculations
Statistical calculations were made using the statistical package Statgraphics, version 5.1 (Statistics Graphic Corp, Rockville, USA). Method comparisons were performed according to Passing and Bablok. s The ROC-(receiveroperating characteristic)-curves were calculated according to standard procedures.P-" IMx® test of Abbott. Since assays for measuring f-PSA were not commercially available at the start of the study we could not determine f-PSA in all samples (Table I) . However, the data confirmed the higher proportion of f-PSA in healthy men and in BPH patients than in PCa patients. We found the mean proportion of f-PSA in all groups studied was in the above mentioned range where PSA determination was independent of the proportion of f-PSA in the sample.
RESULTS AND DISCUSSION
On the other hand, using the equimolarresponse LIA-mat assay the PSA concentrations measured in healthy persons, in BPH patients and PCa patients were significantly lower compared to the Tandem's and AxSymCll: tests (Table I) . Comparisons between the LIA-matJt) test and the other two tests considering each group separately showed that all six intercepts and slopes of the linear regression were significantly different from zero or I (Table 2) . Comparing the intercepts between the groups, we found those in the BPH group significantly higher than those in the cancer patients when the results between the LIA-mat® and Tandem'S tests were compared. The comparison between the Ll Avmat'" and Axsymw test showed the same tendency. These data were in contrast to the results obtained with the pure PSA solutions since:
The LIA-mat'"I!! test gave lower serum PSA values than the other two assays, and 2 Different slopes of the regression equations were obtained with sera from BPH and PCa patients although the Ll Avmat'" test did not show different reactivity with pure solutions of f-PSA and ACT-PSA.
On the other hand, Tillyer et al" found the PSA values measured by Roche Cobasb'Core PSA assay were on average 25% lower than those obtained with the Tandern'v-E PSA assay. Lower concentrations were found although the Roche Cobas'e'Core PSA assay was much more responsive to f-PSA than the Tandernw-E PSA assay and corresponded to a skewed-response PSA assay.' Whatever the reason for these discrepancies is, discordant PSA values measured by different tests are not solely due to the equimolar or skewed-response of the PSA in the corresponding assays. Numerous additional factors such as the composition of the calibrator and diluent, the value assigned to the calibrator, the matrix effect, the test design and the specificity of the antibodies also influence the results.F It is expected that the international stand'ardization of PSA assays against the PSA-ACT complex will overcome most of these discrepancies. 13 Despite the differences among the PSA assays studied, receiver-operating characteristic curve analyses of the three assays were not different (Fig. 2) . The PSA assays gave similar clinical discrimination when method-dependent limits were used. To discriminate between healthy men and PCa patients with a sensitivity of about 90% and a specificity of about 80%, the cut-off limits for the Tandem'" test, Ax Sym'" test, and LIA-matcH) test would be 3'7, 3·3, and 1'6/lg/L, respectively, Thus, only if kit-specific cut-off values are used, will similar clinical results be obtained. Thus use of a general cut-off limit of 4/lg/L, often used in urological practice, may not be appropriate.
The assays studied may differ in their diagnostic power of detecting tumour recurrence following treatment. For example, Bluestein et al. 14 (1 -Specificity) PSA assay found that the ACS PSA assay showed greater clinical sensitivity in detecting disease progression or regression. They assumed that polyconal antibodies used in the ACS PSA assay react with forms of PSA undetectable in strictly monoclonal assays.
In conclusion, as already assumed by other authors'S" the equimolar-response PSA assay does not seem to offer any diagnostic advantage over the skewed-response PSA assay. At present, it is more important to take into account the method-dependent PSA reference limits'? in the absence of an authorized PSA reference rnateriaI. 13 
